Table 5.

The frequency of adverse events in both groups, safety analysis set

Adverse events, n (%)		Cerebrolysin (n=30)	Placebo (n=30)
Bronchopneumonia	n, %	1 (3.33)	2 (6.66)
Deep venous thrombosis	n, %	1 (3.33)	0 (0)
Urinary infections	n, %	7 (23.33)	7 (23.33)
Pressure ulcers	n, %	0 (0)	1 (3.33)
Falls	n, %	3 (10)	2 (6.66)
Depression	n, %	2 (6.66)	3 (10)
Psychomotor agitation	n, %	2 (6.66)	1 (3.33)
Sleep disturbances	n, %	4 (13.33)	4 (13.33)
Hypertension	n, %	6 (20)	5 (16.66)
Stable angina	n, %	1 (3.33)	1 (3.33)
Abdominal pains	n, %	3 (10)	4 (13.33)
Catheter phlebitis	n, %	7 (23.33)	8 (26.66)
Articular pains	n, %	3 (10)	4 (13.33)
Total		40	42